XP-102 / Xynomic, Boehringer Ingelheim - LARVOL DELTA

ENHANCE: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (clinicaltrials.gov) - P1/2 | N=221 | Not yet recruiting | Sponsor: Xynomic Pharmaceuticals, Inc. | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2025 ➔ Dec 2027

Trial completion date • Trial primary completion date • Colorectal Cancer • Endocrine Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • BRAF

ENHANCE: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (clinicaltrials.gov) - P1/2 | N=221 | Not yet recruiting | Sponsor: Xynomic Pharmaceuticals, Inc. | Trial primary completion date: Dec 2024 ➔ Dec 2025

Combination therapy • Metastases • Trial primary completion date • Colorectal Cancer • Endocrine Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • BRAF

ENHANCE: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (clinicaltrials.gov) - P1/2 | N=221 | Not yet recruiting | Sponsor: Xynomic Pharmaceuticals, Inc. | Initiation date: Jun 2022 ➔ Dec 2022

Combination therapy • Trial initiation date • Colorectal Cancer • Endocrine Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • BRAF

ENHANCE: A Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (clinicaltrials.gov) - P1/2 | N=221 | Not yet recruiting | Sponsor: Xynomic Pharmaceuticals, Inc.

Combination therapy • New P1/2 trial • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • BRAF